CAS 453562-69-1: Motesanib
Description:Motesanib is a small molecule that functions primarily as a tyrosine kinase inhibitor, targeting various receptor tyrosine kinases involved in angiogenesis and tumor growth. It is particularly noted for its activity against vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and fibroblast growth factor receptors (FGFRs). Motesanib has been investigated for its potential therapeutic applications in treating various cancers, including non-small cell lung cancer and other solid tumors. The compound is characterized by its ability to inhibit tumor vascularization, thereby limiting the supply of nutrients and oxygen to tumors. In terms of its chemical structure, Motesanib features a complex arrangement that contributes to its biological activity, although specific structural details are not provided here. As with many investigational drugs, the pharmacokinetics, efficacy, and safety profile of Motesanib have been subjects of clinical studies, with varying results influencing its development in oncology.
Formula:C22H23N5O
InChI:InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)
InChI key:InChIKey=RAHBGWKEPAQNFF-UHFFFAOYSA-N
SMILES:O=C(NC1=CC=C2C(=C1)NCC2(C)C)C3=CC=CN=C3NCC=4C=CN=CC4
- Synonyms:
- 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-
- Amg 706
- N-(2,3-Dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide
- N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide
